2. Search Result
Search Result
Results for "

Formyl Peptide Receptor

" in MedChemExpress (MCE) Product Catalog:

47

Inhibitors & Agonists

24

Peptides

1

Inhibitory Antibodies

1

Natural
Products

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P0224
    N-Formyl-Met-Leu-Phe
    Maximum Cited Publications
    16 Publications Verification

    fMLP; N-Formyl-MLF

    		 TNF Receptor Inflammation/Immunology
    N-Formyl-Met-Leu-Phe (fMLP; N-Formyl-MLF) is a chemotactic peptide and a specific ligand of N-formyl peptide receptor (FPR). N-Formyl-Met-Leu-Ph is reported to inhibit TNF-alpha secretion.
    N-Formyl-Met-Leu-Phe
  • HY-P1122
    Cyclosporin H
    3 Publications Verification

    		 Formyl Peptide Receptor (FPR) Infection Inflammation/Immunology
    Cyclosporin H is a selective and potent inhibitor of FPR-1 (formyl peptide receptor 1). Cyclosporin H, a viral transduction enhancer, increases lentiviral transduction up to 10-fold in human cord blood-derived hematopoietic stem and progenitor cells (HSPCs). Cyclosporin H displays an additive effect when combined with Rapamycin (HY-10219) or Prostaglandin E2 (HY-101952). Cyclosporin H lacks immunosuppressant activity of Cyclosporin A.
    Cyclosporin H
  • HY-P1119
    WRW4
    10+ Cited Publications

    		 Formyl Peptide Receptor (FPR) Neurological Disease
    WRW4, a specific formyl peptide receptor-like 1 (FPRL1) antagonist, inhibits WKYMVm binding to FPRL1 with an IC50 of 0.23 μM. WRW4 specifically inhibits the increase in intracellular calcium by the FPRL1 agonists MMK-1, amyloid beta42 (Abeta42) peptide, and F peptide .
    WRW4
  • HY-101283
    HCH6-1
    5 Publications Verification

    		 Formyl Peptide Receptor (FPR) Inflammation/Immunology
    HCH6-1 is a potent and competitive dipeptide antagonist of Formyl peptide receptor 1 (FPR1). HCH6-1 inhibits chemotaxis, superoxide anion generation, and elastase release in human neutrophils specifically activated by fMLF (an FPR1 agonist). HCH6-1 has protective effects against acute lung injury (ALI) in vivo and can be used for the research of FPR1-involved inflammatory lung diseases .
    HCH6-1
  • HY-P1120
    WKYMVm

    WKYMVm-amide; W-Peptide

    		 Formyl Peptide Receptor (FPR) PERK Apoptosis Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    WKYMVm is a selective formylpeptide receptor 2 (FPR2) agonist. WKYMVm has a powerful anti-inflammatory effect that can reduce lung injury and spinal cord injury. WKYMVm ameliorates obesity by regulating lipid metabolism and leptin signaling. WKYMVm is involved in the regulation of immune cells by activating FPRs. WKYMVm can promote the chemotactic migration of immune cells and inhibit the apoptosis of phagocytes. In addition, WKYMVm may play a favorable or unfavorable role in tumors, depending on the type of tumor .
    WKYMVm
  • HY-P4744
    LL-37 amide
    2 Publications Verification

    		 Formyl Peptide Receptor (FPR) Bacterial Infection Cancer
    LL-37 amide is a selective agonist of formyl peptide receptor-like FPRL1, effectively inhibiting periodontal pathogens (ED99=8.5-8.7 μg/mL). LL-37 amide exerts its bactericidal effect by activating FPRL1-mediated immune cell chemotaxis and disrupting bacterial cell membrane integrity. It can also regulate inflammatory responses (inhibiting the release of factors such as TNF-α) and promote angiogenesis. Amidation modification reduces its sensitivity to serum inhibition and improves its stability. LL-37 amide possesses key activities in bactericidal action, immunomodulation, and wound healing, and is mainly used in research on infection-related diseases such as periodontal disease and deep tissue injuries (pressure ulcers), and wound healing .
    LL-37 amide
  • HY-131180
    BMS-986235
    1 Publications Verification

    LAR-1219

    		 Formyl Peptide Receptor (FPR) Cardiovascular Disease
    BMS-986235 (LAR-1219) is a selective, orally active formyl peptide receptor 2 (FPR2) agonist, with EC50s of 0.41 nM and 3.4 nM for hFPR2 and mFPR2, respectively. BMS-986235 has potential for the prevention of heart failure .
    BMS-986235
  • HY-172435
    Rezuforimod

    AGN-232411; AG-80308; AGN-411

    		 Formyl Peptide Receptor (FPR) Neurological Disease
    Rezuforimod (AGN-232411; AG-80308) is an ophthalmic solution targeting the formyl peptide receptor (FPR) pathway. Rezuforimod exerts anti-inflammatory effects by targeting the formyl peptide receptor pathway. Administered topically, Rezuforimod significantly reduces the corneal conjunctival staining score and improves ocular discomfort symptoms, with no serious adverse events reported and favorable overall safety profile. Rezuforimod shows remarkable potential to serve as a novel therapeutic option for dry eye disease .
    Rezuforimod
  • HY-19574
    FPR Agonist 43
    2 Publications Verification

    		 Formyl Peptide Receptor (FPR) Inflammation/Immunology
    FPR Agonist 43 (compound 43) is a dual formyl peptide receptor 1 (FPR1) and formyl peptide receptor 2 (FPR2)/ALX agonist .
    FPR Agonist 43
  • HY-103286
    PD176252
    2 Publications Verification

    		 Bombesin Receptor Cancer
    PD176252 is a potent antagonist of neuromedin-B preferring (BB1) and gastrin-releasing peptide-preferring (BB2) receptor with Kis of 0.17 nM and 1 nM for human BB1 and BB2 receptors, and 0.66 nM, 16 nM for Rat BB1 and BB2 receptors, respectively; PD176252 is also an agonist of N-Formyl peptide receptor1/2 (FPR1/FPR2), with EC50s of 0.31 and 0.66 μM in HL-60 cells.
    PD176252
  • HY-P1795
    Boc-dPhe-Leu-dPhe-Leu-Phe
    2 Publications Verification

    		 Formyl Peptide Receptor (FPR) Inflammation/Immunology
    Boc-dPhe-Leu-dPhe-Leu-Phe (Boc-fLfLF) is a selective N-formyl peptide receptor1 (FPR1) antagonist. Boc-dPhe-Leu-dPhe-Leu-Phe inhibits fMIFL(HY-P0224)-induced NADPH oxidase activity. Boc-dPhe-Leu-dPhe-Leu-Phe can be used for the study of inflammation .
    Boc-dPhe-Leu-dPhe-Leu-Phe
  • HY-P10724
    fMIFL

    		Formyl Peptide Receptor (FPR) Bacterial Infection
    fMIFL is a formyl tetrapeptide derived from Staphylococcus aureus, and also an agonist of mouse formyl peptide receptor 1 (mFPR1). It exhibits nanomolar activity against mFPR1 and micromolar activity against mFPR2. fMIFL is applicable to studies related to bacterial infections .
    fMIFL
  • HY-124071
    ACT-389949

    		Formyl Peptide Receptor (FPR) Inflammation/Immunology
    ACT-389949 is a first-in-class, potent and selective and agonist of formyl peptide receptor type 2 (FPR2)/Lipoxin A4 receptor (ALX), with an EC50 of 3 nM for FPR2/ALX internalization into monocytes. ACT-389949 has potential for the treatment of inflammatory disorders .
    ACT-389949
  • HY-173591
    T0080

    		Formyl Peptide Receptor (FPR) Apoptosis Cardiovascular Disease Neurological Disease Inflammation/Immunology
    T0080 is a central nervous system-penetrant FPR1 inhibitor. By functionally blocking the FPR1 signaling pathway, T0080 effectively reduces neutrophil infiltration into ischemic brain tissue and maintains the integrity of the blood-brain barrier. T0080 alleviates tPA-associated hemorrhagic transformation, inhibits demyelination responses and the expression of NOX2. T0080 also possesses anti-apoptotic (apoptosis) and anti-inflammatory properties, thereby protecting myelin and reducing neurological deficits. T0080 is widely used in studies related to ischemic stroke complicated by hemorrhagic transformation after tPA thrombolysis, as well as multiple sclerosis .
    T0080
  • HY-P1117
    MMK1
    1 Publications Verification

    		 Formyl Peptide Receptor (FPR) Calcium Channel Neurological Disease Inflammation/Immunology
    MMK1 is a potent and selective human formyl peptide receptor like-1 (FPRL-1/FPR2) agonist with EC50s of <2 nM and >10000 nM for FPRL-1 and FPR1, respectively. MMK1 is a potent chemotactic and calcium-mobilizing agonist. MMK1 potently activates phagocytic leukocytes and enhances Pertussis Toxin-sensitive production by human monocytes of proinflammatory cytokines IL-1b and IL-6. MMK1 exerts anxiolytic-like activity .
    MMK1
  • HY-128113
    AG-09/1

    		Formyl Peptide Receptor (FPR) Inflammation/Immunology
    AG-09/1 is a specific formyl peptide receptor 1 (FPR1) agonist. N-formyl peptide receptors (FPR) are important in host defense .
    AG-09/1
  • HY-156293
    FPR1 antagonist 1

    		Formyl Peptide Receptor (FPR) Apoptosis Cancer
    FPR1 antagonist 1 (compound 24a) is a formyl peptide receptor 1 (FPR1) antagonist with an IC50 of 25 nM. FPR1 antagonist 1 inhibits cell growth through a combined effect on cell proliferation and apoptosis and reduces cell migration, while inducing an increase in angiogenesis .
    FPR1 antagonist 1
  • HY-P4744A
    LL-37 amide TFA
    2 Publications Verification

    		 Formyl Peptide Receptor (FPR) Bacterial Infection Cancer
    LL-37 amide TFA is a selective agonist of formyl peptide receptor-like FPRL1, effectively inhibiting periodontal pathogens (ED99=8.5-8.7 μg/mL). LL-37 amide TFA exerts its bactericidal effect by activating FPRL1-mediated immune cell chemotaxis and disrupting bacterial cell membrane integrity. It can also regulate inflammatory responses (inhibiting the release of factors such as TNF-α) and promote angiogenesis. Amidation modification reduces its sensitivity to serum inhibition and improves its stability. LL-37 amide TFA possesses key activities in bactericidal action, immunomodulation, and wound healing, and is mainly used in research on infection-related diseases such as periodontal disease and deep tissue injuries (pressure ulcers), and wound healing .
    LL-37 amide TFA
  • HY-103473A
    Boc-MLF TFA
    4 Publications Verification

    Boc-Met-Leu-Phe-OH TFA

    		 Formyl Peptide Receptor (FPR) Inflammation/Immunology
    Boc-MLF (TFA) is a peptide, used as a specific formyl peptide receptor (FPR) antagonist, also inhibits the signaling through formyl peptide receptor like 1 (FPRL1) at higher concentrations .
    Boc-MLF TFA
  • HY-103473
    Boc-MLF
    4 Publications Verification

    Boc-Met-Leu-Phe-OH

    		 Formyl Peptide Receptor (FPR) Inflammation/Immunology
    Boc-MLF is a formyl peptide receptor (FPR) antagonist, and reduces superoxide production induced by fMLF with an IC50 of 0.63 μM .
    Boc-MLF
  • HY-P1118
    Ac9-25

    		Formyl Peptide Receptor (FPR) Inflammation/Immunology
    Ac9-25, a N-terminal peptide of Annexin I, acts as a formyl peptide receptor (FPR) agonist and activates the neutrophil NADPH oxidase through FPR .
    Ac9-25
  • HY-P2355
    BOC-FlFlF

    BOC2; Boc-Phe-dLeu-Phe-dLeu-Phe

    		 Formyl Peptide Receptor (FPR) Inflammation/Immunology
    BOC-FlFlF (Boc-Phe-dLeu-Phe-dLeu-Phe) is a selective FPR1 antagonist. Boc-FlFlF has an apparent dissociation constant (KD) of 230 nM as determined by the intracellular calcium mobilization assay. Boc-FlFlF can be used for the study of inflammation .
    BOC-FlFlF
  • HY-P1121A
    WKYMVM-NH2 TFA

    		Formyl Peptide Receptor (FPR) Inflammation/Immunology
    WKYMVM-NH2 TFA is a potent N-formyl peptide receptor (FPR1) and FPRL1/2 agonist, also activates several leukocyte effector functions such as chemotaxis, mobilization of complement receptor-3, and activation of the NADPH oxidase .
    WKYMVM-NH2 TFA
  • HY-117971
    BVT173187

    		CXCR Formyl Peptide Receptor (FPR) Others
    BVT173187 is a selective inhibitor of the neutrophil formyl peptide receptor FPR1, with activity that inhibits FPR1 activation. BVT173187 inhibits FPR1 agonist-induced activation in neutrophils, reduces adhesion molecule mobilization and superoxide anion production, and has inhibitory activity on FPR1 similar to that of earlier described peptide antagonists, but also has effects on C5aR and CXCR signaling.
    BVT173187
  • HY-P3318
    Boc-Phe-Leu-Phe-Leu-Phe

    L-BOC2

    		 Leukotriene Receptor Inflammation/Immunology
    Boc-Phe-Leu-Phe-Leu-Phe (Boc-FLFLF) is a N-formyl peptide receptors (FPR) inhibitor. Boc-Phe-Leu-Phe-Leu-Phe abolishes the FMLP-induced release of peptide leukotrienes. Boc-Phe-Leu-Phe-Leu-Phe inhibits the sprouting of human umbilical vein endothelial cell (HUVEC) spheroids mediated by proliferative diabetic retinopathy (PDR) vitreous and vascular endothelial growth factor (VEGF) respectively in a three-dimensional fibrin gel. Boc-Phe-Leu-Phe-Leu-Phe inhibits the anti-inflammatory and antifibrotic effects of Ac2-26 (HY-P1098). Boc-Phe-Leu-Phe-Leu-Phe can be used for the study of immunology .
    Boc-Phe-Leu-Phe-Leu-Phe
  • HY-P1591
    N-Formyl-Nle-Leu-Phe-Nle-Tyr-Lys

    For-Nle-Leu-Phe-Nle-Tyr-Lys-OH

    		 Formyl Peptide Receptor (FPR) Inflammation/Immunology
    N-Formyl-Nle-Leu-Phe-Nle-Tyr-Lys TFA (For-Nle-Leu-Phe-Nle-Tyr-Lys-OH TFA) is a formyl peptide receptor (FPR) agonist .
    N-Formyl-Nle-Leu-Phe-Nle-Tyr-Lys
  • HY-103472
    FPR-A14
    1 Publications Verification

    		 Formyl Peptide Receptor (FPR) Neurological Disease
    FPR-A14 is a potent formyl peptide receptor (FPR) agonist. FPR-A14 is a potent activator of neutrophil Ca 2+ mobilization and chemotaxis with EC50s of 630 nM and 42 nM, respectively. FPR-A14 induces cell differentiation .
    FPR-A14
  • HY-P1756
    N-Formyl-Met-Ala-Ser

    		Formyl Peptide Receptor (FPR) Inflammation/Immunology
    N-Formyl-Met-Ala-Ser is a peptide, binds to formyl peptide receptors on neutrophils.
    N-Formyl-Met-Ala-Ser
  • HY-N8152
    Randialic acid B

    		Reactive Oxygen Species (ROS) Inflammation/Immunology
    Randialic acid B, a triterpenoid compound, is a formyl peptide receptor 1 (FPR1) antagonist. Randialic acid B blocks FPR1 in human neutrophils and attenuates psoriasis-like inflammation in vivo .
    Randialic acid B
  • HY-130675
    (±)15-HEPE

    (±)15-hydroxyeicosapentaenoic acid; 15-OHEPA

    		 Lipoxygenase Bacterial Metabolic Disease
    (±)15-HEPE is a racemic mixture of the monohydroxy fatty acids 15(R)-HEPE and 15(S)-HEPE (HY-130675A). (±)15-HEPE is active against P. acnes and S. aureus (MICs = 128 and 512 mg/L, respectively). It inhibits aggregation of isolated rat neutrophils induced by the formyl peptide receptor agonist fMLP (IC50 = 4.7 µM). Bronchoalveolar lavage fluid (BALF) levels of (±)15-HEPE are increased in patients with allergic asthma or COVID-19.
    (±)15-HEPE
  • HY-P11491
    Ac2-26 (mouse)

    		Formyl Peptide Receptor (FPR) Reactive Oxygen Species (ROS) Inflammation/Immunology
    Ac2-26 (mouse) is the N-terminal active peptide of Annexin A1 (AnxA1). Ac2-26 (mouse) regulates the inflammatory response by modulating the formyl peptide receptor (FPR) signaling pathway. Ac2-26 (mouse) can promote the release of chemokines and inhibit the production of ROS. Ac2-26 (mouse) can be used for the research of inflammation, such as rheumatoid arthritis .
    Ac2-26 (mouse)
  • HY-156294
    FPR1 antagonist 2

    		Formyl Peptide Receptor (FPR) Apoptosis Cancer
    FPR1 antagonist 2 (compound 25b) is a formyl peptide receptor 1 (FPR1) antagonist with an IC50 of 70 nM. FPR1 antagonist 2 inhibits cell growth through a combined effect on cell proliferation and apoptosis and reduces cell migration, while inducing an increase in angiogenesis .
    FPR1 antagonist 2
  • HY-110246
    Quin C1

    		Formyl Peptide Receptor (FPR) Inflammation/Immunology
    Quin C1 is a highly specific and potent agonist for formyl peptide receptor 2 (FPR2/ALX). Quin-C1 significantly reduces the neutrophil and lymphocyte counts in BALF, diminishes expression of TNF-α, IL-1β, KC, and TGF-β1, and decreases collagen deposition in lung tissue. Quin C1 has the potential for the research of lung injury .
    Quin C1
  • HY-P1117A
    MMK1 TFA

    		Formyl Peptide Receptor (FPR) Calcium Channel Neurological Disease Inflammation/Immunology
    MMK1 TFA is a potent and selective human formyl peptide receptor like-1 (FPRL-1/FPR2) agonist with EC50s of <2 nM and >10000 nM for FPRL-1 and FPR1, respectively. MMK1 TFA is a potent chemotactic and calcium-mobilizing agonist. MMK1 TFA potently activates phagocytic leukocytes and enhances Pertussis Toxin-sensitive production by human monocytes of proinflammatory cytokines IL-1b and IL-6. MMK1 TFA exerts anxiolytic-like activity .
    MMK1 TFA
  • HY-P1591A
    N-Formyl-Nle-Leu-Phe-Nle-Tyr-Lys TFA

    For-Nle-Leu-Phe-Nle-Tyr-Lys-OH TFA

    		 Formyl Peptide Receptor (FPR) Inflammation/Immunology
    N-Formyl-Nle-Leu-Phe-Nle-Tyr-Lys TFA (For-Nle-Leu-Phe-Nle-Tyr-Lys-OH TFA) is a formyl peptide receptor (FPR) agonist .
    N-Formyl-Nle-Leu-Phe-Nle-Tyr-Lys TFA
  • HY-P1118A
    Ac9-25 TFA

    		Formyl Peptide Receptor (FPR) Inflammation/Immunology
    Ac9-25 TFA, a N-terminal peptide of Annexin I, acts as a formyl peptide receptor (FPR) agonist and activates the neutrophil NADPH oxidase through FPR .
    Ac9-25 TFA
  • HY-P2355A
    BOC-FlFlF TFA

    BOC2 TFA; Boc-Phe-dLeu-Phe-dLeu-Phe TFA

    		 Formyl Peptide Receptor (FPR) Inflammation/Immunology
    BOC-FlFlF (TFA) (Boc-Phe-dLeu-Phe-dLeu-Phe (TFA)) is a selective FPR1 antagonist. BOC-FlFlF has an apparent dissociation constant (KD) of 230 nM as determined by the intracellular calcium mobilization assay. BOC-FlFlF can be used for the study of inflammation .
    BOC-FlFlF TFA
  • HY-P5469
    WRW4-OH

    		Formyl Peptide Receptor (FPR) Others
    WRW4-OH is a biological active peptide. (This peptide inhibits binding of one of formyl peptide receptor-like 1 (FPRL1) agonists WKYMVm to its specific receptor. FPRL1 is an important classical chemoattractant receptor that is expressed in phagocytic cells in the peripheral blood and brain. Activation of FPRL1 is closely related to inflammatory responses in the host defense mechanism and neurodegenerative disorders.)
    WRW4-OH
  • HY-P1119A
    WRW4 TFA

    		Formyl Peptide Receptor (FPR) Neurological Disease
    WRW4 TFA, a specific formyl peptide receptor-like 1 (FPRL1) antagonist, inhibits WKYMVm binding to FPRL1 with an IC50 of 0.23 μM. WRW4 TFA specifically inhibits the increase in intracellular calcium by the FPRL1 agonists MMK-1, amyloid beta42 (Abeta42) peptide, and F peptide .
    WRW4 TFA
  • HY-176403
    FPR1 antagonist 3

    		Formyl Peptide Receptor (FPR) Inflammation/Immunology
    FPR1 antagonist 3 (compound 10) is a potent and selective FPR1 antagonist. FPR1 antagonist 3 inhibits superoxide anion generation and elastase release with IC50s of 0.33 and 0.84 μM, respectively .
    FPR1 antagonist 3
  • HY-178144
    FPR2 agonist 5

    		Formyl Peptide Receptor (FPR) Calcium Channel Interleukin Related NO Synthase Neurological Disease Inflammation/Immunology
    FPR2 agonist 5 is a selective Formyl Peptide Receptor 2 (FPR2) agonist. FPR2 agonist 5 induces Ca 2+ mobilization in FPR2-HL60 transfected cells with an EC50 of 1.2 μM and causes FPR2 desensitization with an IC50 of 0.32 μM. FPR2 agonist 5 exerts neuroprotective effects by mitigating LDH release, NO production, IL-1β, IL-6, IL-33, and IL-10 levels in LPS (HY-D1056)-induced mouse primary microglial cells. FPR2 agonist 5 can be used for the study of neuroinflammatory-related diseases .
    FPR2 agonist 5
  • HY-P11704
    f-MKKFRW

    		Formyl Peptide Receptor (FPR) Bacterial Neurological Disease
    f-MKKFRW is a selective mouse formyl peptide receptor 3 (Fpr3) activator and bacterial MgrB-derived peptide motif. f-MKKFRW activates Fpr3 to trigger downstream signaling and calcium responses in Fpr3-expressing cells. f-MKKFRW stimulates a subset of mouse vomeronasal sensory neurons in the accessory olfactory system to evoke calcium responses. f-MKKFRW drives innate avoidance behavior in mice via nasal contact .
    f-MKKFRW
  • HY-P991864
    Annexuzlimab

    MDX-124

    		 Formyl Peptide Receptor (FPR) Cancer
    Annexuzlimab is a humanised IgG1 monoclonal antibody which specifically binds to ANXA1 disrupting its interaction with formyl peptide receptors 1 and 2 (FPR1/2). Annexuzlimab arrests cell cycle progression with cancer cells accumulating in the G1 phase. Annexuzlimab targets secreted ANXA1, preventing FPR1/2 activation and reducing cancer progression. Annexuzlimab can be used for the research of triple negative breast cancer, pancreatic cancer and osteosarcoma .
    Annexuzlimab
  • HY-103286R
    PD176252 (Standard)

    		Reference Standards Bombesin Receptor Cancer
    PD176252 (Standard) is the analytical standard of PD176252 (HY-103286). This product is intended for research and analytical applications. PD176252 is a potent antagonist of neuromedin-B preferring (BB1) and gastrin-releasing peptide-preferring (BB2) receptor with Kis of 0.17 nM and 1 nM for human BB1 and BB2 receptors, and 0.66 nM, 16 nM for Rat BB1 and BB2 receptors, respectively; PD176252 is also an agonist of N-Formyl peptide receptor1/2 (FPR1/FPR2), with EC50s of 0.31 and 0.66 μM in HL-60 cells.
    PD176252 (Standard)
  • HY-103472R
    FPR-A14 (Standard)

    		Reference Standards Formyl Peptide Receptor (FPR) Neurological Disease
    FPR-A14 (Standard) is the analytical standard of FPR-A14 (HY-103472). This product is intended for research and analytical applications. FPR-A14 is a potent formyl peptide receptor (FPR) agonist. FPR-A14 is a potent activator of neutrophil Ca2+ mobilization and chemotaxis with EC50s of 630 nM and 42 nM, respectively. FPR-A14 induces cell differentiation .
    FPR-A14 (Standard)
  • HY-101283R
    HCH6-1 (Standard)

    		Formyl Peptide Receptor (FPR) Reference Standards Inflammation/Immunology
    HCH6-1 (Standard) is the analytical standard of HCH6-1 (HY-101283). This product is intended for research and analytical applications. HCH6-1 is a potent and competitive dipeptide antagonist of Formyl peptide receptor 1 (FPR1). HCH6-1 inhibits chemotaxis, superoxide anion generation, and elastase release in human neutrophils specifically activated by fMLF (an FPR1 agonist). HCH6-1 has protective effects against acute lung injury (ALI) in vivo and can be used for the research of FPR1-involved inflammatory lung diseases .
    HCH6-1 (Standard)
  • HY-181822
    BMS-986331

    		Formyl Peptide Receptor (FPR) Arrestin PKA Interleukin Related Cardiovascular Disease
    BMS-986331 is an orally active selective N-Formyl Peptide Receptor 2 (FPR2) agonist with an EC50 of 0.5 nM in humans and 1 nM in rats. BMS-986331 activates Gαi2, GαoA, Gα12, Gα13 signaling pathways, recruits β-arrestin1 and β-arrestin2, and inhibits downstream cAMP. BMS-986331 induces the expression and release of the pro-resolution cytokine IL-10. BMS-986331 improves cardiac structure and function in a rat model of heart failure induced by permanent coronary artery occlusion. BMS-986331 can be used for the research of heart failure .
    BMS-986331

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: